Literature DB >> 10483724

Up-regulation of narX, encoding a putative 'fused nitrate reductase' in anaerobic dormant Mycobacterium bovis BCG.

B Hutter1, T Dick.   

Abstract

Mycobacterium tuberculosis and its closely related but non-pathogenic relative M. bovis Bacille Calmette-Guèrin (BCG) have the capability to adapt to anaerobiosis by shifting down from aerobic growth to a state of non-replicating persistence or dormancy. Here, we report the results of a comparative Northern analysis of 23 genes identified in the tubercle bacillus genome project that might play a role in the energy metabolism under anaerobic conditions. The expression of a majority of the genes was found to be down-regulated in the dormant BCG culture. However, the mRNA level for narX, a putative 'fused nitrate reductase' not found in other bacteria, was strongly up-regulated in anaerobic dormant bacilli. narX is the first transcriptionally induced gene in anaerobic dormant mycobacteria and might be a useful marker for monitoring the dormancy response in infected animals.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10483724     DOI: 10.1111/j.1574-6968.1999.tb13760.x

Source DB:  PubMed          Journal:  FEMS Microbiol Lett        ISSN: 0378-1097            Impact factor:   2.742


  20 in total

1.  Proteins of Mycobacterium bovis BCG induced in the Wayne dormancy model.

Authors:  C Boon; R Li; R Qi; T Dick
Journal:  J Bacteriol       Date:  2001-04       Impact factor: 3.490

2.  Genomic DNA standards for gene expression profiling in Mycobacterium tuberculosis.

Authors:  Adel M Talaat; Susan T Howard; Walker Hale; Rick Lyons; Harold Garner; Stephen Albert Johnston
Journal:  Nucleic Acids Res       Date:  2002-10-15       Impact factor: 16.971

3.  Mycobacterium bovis BCG response regulator essential for hypoxic dormancy.

Authors:  Calvin Boon; Thomas Dick
Journal:  J Bacteriol       Date:  2002-12       Impact factor: 3.490

4.  Metagenomic covariation along densely sampled environmental gradients in the Red Sea.

Authors:  Luke R Thompson; Gareth J Williams; Mohamed F Haroon; Ahmed Shibl; Peter Larsen; Joshua Shorenstein; Rob Knight; Ulrich Stingl
Journal:  ISME J       Date:  2016-07-15       Impact factor: 10.302

5.  Dependence of Mycobacterium bovis BCG on anaerobic nitrate reductase for persistence is tissue specific.

Authors:  Christian Fritz; Silvia Maass; Andreas Kreft; Franz-Christoph Bange
Journal:  Infect Immun       Date:  2002-01       Impact factor: 3.441

6.  In situ detection of Mycobacterium tuberculosis transcripts in human lung granulomas reveals differential gene expression in necrotic lesions.

Authors:  Gael Fenhalls; Liesel Stevens; Lorraine Moses; Juanita Bezuidenhout; Joanna C Betts; Paul van Helden Pv; Pauline T Lukey; Ken Duncan
Journal:  Infect Immun       Date:  2002-11       Impact factor: 3.441

7.  Polymorphic nucleotide within the promoter of nitrate reductase (NarGHJI) is specific for Mycobacterium tuberculosis.

Authors:  Marion Stermann; Antje Bohrssen; Catharina Diephaus; Silvia Maass; Franz-Christoph Bange
Journal:  J Clin Microbiol       Date:  2003-07       Impact factor: 5.948

8.  A family of acr-coregulated Mycobacterium tuberculosis genes shares a common DNA motif and requires Rv3133c (dosR or devR) for expression.

Authors:  Matthew A Florczyk; Lee Ann McCue; Anjan Purkayastha; Egidio Currenti; Meyer J Wolin; Kathleen A McDonough
Journal:  Infect Immun       Date:  2003-09       Impact factor: 3.441

9.  Mycobacterium bovis BCG vaccine strains lack narK2 and narX induction and exhibit altered phenotypes during dormancy.

Authors:  Ryan W Honaker; Amanda Stewart; Stephanie Schittone; Angelo Izzo; Michèl R Klein; Martin I Voskuil
Journal:  Infect Immun       Date:  2008-03-24       Impact factor: 3.441

10.  A promoter mutation causes differential nitrate reductase activity of Mycobacterium tuberculosis and Mycobacterium bovis.

Authors:  Marion Stermann; Ludwig Sedlacek; Silvia Maass; Franz-Christoph Bange
Journal:  J Bacteriol       Date:  2004-05       Impact factor: 3.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.